Sign in

    Dipesh Patel

    Research Analyst at H.C. Wainwright & Co.

    Dipesh Patel is an equity research analyst at H.C. Wainwright & Co., where he specializes in covering emerging healthcare and biotechnology companies. He is known for providing in-depth investment research on firms such as Rosellini Scientific and several innovative life sciences start-ups, contributing to investors’ decision-making through actionable insights. Patel previously held roles at First Quadrant Advisory, Vizient, and also has experience as a private investor, bringing a wide perspective to his analysis since joining H.C. Wainwright. He holds industry-related credentials and is experienced in financial modeling and securities analysis, bolstered by hands-on experience in both advisory and investment functions.

    Dipesh Patel's questions to SELB leadership

    Dipesh Patel's questions to SELB leadership • Q1 2023

    Question

    Dipesh Patel asked about the future of ImmTOR in gene therapy following the MMA program pause, the status of the Sobi relationship and milestones, the development strategy for ImmTOR IL, and for any analysis of secondary endpoints or non-responder characteristics from the DISSOLVE studies.

    Answer

    CEO Carsten Brunn responded that ImmTOR remains well-suited for gene therapy, which has always been a partnering strategy, evidenced by the recent Astellas deal. He confirmed the Sobi relationship is strong and milestones are on track. He stated Selecta plans to advance ImmTOR IL in liver diseases internally without a partner for now. Finally, he noted that analysis of DISSOLVE secondary endpoints and non-responder data is ongoing and will be shared at a future scientific conference.

    Ask Fintool Equity Research AI

    Dipesh Patel's questions to SELB leadership • Q1 2023

    Question

    Dipesh Patel asked about the future of ImmTOR in gene therapy following the MMA study pause, the impact of market conditions on the Sobi relationship, the development strategy for ImmTOR IL, and for details on secondary endpoints and non-responder characteristics from the DISSOLVE studies.

    Answer

    CEO Carsten Brunn affirmed that ImmTOR is well-suited for gene therapy, which remains a partnering strategy, citing the recent Astellas deal. He stated the Sobi relationship is strong and unaffected by market conditions, driven by positive Phase III data. He clarified that Selecta intends to develop ImmTOR IL for liver diseases internally without a partner for now. Regarding the DISSOLVE data, he noted that analysis of secondary endpoints and non-responders is ongoing and will be shared at a future scientific conference.

    Ask Fintool Equity Research AI

    Dipesh Patel's questions to SELB leadership • Q1 2023

    Question

    Dipesh Patel asked about the future of ImmTOR in gene therapy following the MMA study pause, whether market conditions affected the Sobi relationship, the clinical strategy for ImmTOR IL, and for details on DISSOLVE secondary endpoints and non-responder data.

    Answer

    CEO Carsten Brunn reaffirmed that ImmTOR is well-suited for gene therapy, which remains a partnering strategy, highlighting the recent Astellas deal. He confirmed the Sobi relationship is strong and unaffected by market conditions. The strategy for ImmTOR IL is to develop it in-house. Finally, he stated that analysis of DISSOLVE secondary endpoints and non-responder characteristics is ongoing and will be disclosed at a future conference.

    Ask Fintool Equity Research AI

    Dipesh Patel's questions to SELB leadership • Q1 2023

    Question

    Dipesh Patel of H.C. Wainwright & Co. asked about the future of ImmTOR in gene therapy, the stability of the Sobi partnership, the development strategy for ImmTOR IL, and for details on DISSOLVE secondary endpoints and non-responder analysis.

    Answer

    CEO Carsten Brunn confirmed ImmTOR is well-suited for gene therapy, highlighting the Astellas partnership, but reiterated it's a partnering strategy. He stated the Sobi relationship is strong and unaffected by market conditions. For ImmTOR IL, the plan is to advance it independently for liver diseases. Brunn deferred questions on DISSOLVE secondary endpoints and non-responder analysis, stating the data is still being analyzed and will be shared at a future conference.

    Ask Fintool Equity Research AI